Arthur F. Kavanaugh

UC San Diego Health System US

Publications

6,710

Citations

H-Index

i10-Index

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis OA

Jasvinder A. Singh, Daniel E. Fürst, Aseem Bharat, Jeffrey R. Curtis, Arthur F. Kavanaugh +25 more

Arthritis Care & Research 2012

1,797

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley Cohen, Karel Pavelká +4 more

Arthritis & Rheumatism 2005

1,780

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Edward Keystone, Arthur F. Kavanaugh, John T. Sharp, H Tannenbaum, Hua Ye +3 more

Arthritis & Rheumatism 2004

1,169

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

Arthur F. Kavanaugh, Laurie S. Davis, Lisa Nichols, Stephen H. Norris, Robert Rothlein +2 more

Arthritis & Rheumatism 1994

264

The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus

Elizabeth W. Karlson, Lawren H. Daltroy, Robert Lew, Elizabeth A. Wright, Alison J. Partridge +8 more

Arthritis & Rheumatism 1997

225

Publications

41 total

AB1107 PSORIATIC ARTHRITIS: IMPROVEMENT IN OUTCOMES BUT PERSISTENT SEX DIFFERENCE - 5 YEAR FOLLOW UP STUDY OF A NORWEGIAN OUTPATIENT CLINIC POPULATION OA

K. Łosińska, B. Michelsen, A. Kavanaugh, M. Korkosz, G. Haugeberg - Annals of the Rheumatic Diseases, 2023

Cited by 7 Semantic Scholar

POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS OA

D. McGonagle, A. Kavanaugh, I. Mcinnes, L. Kristensen, J. Merola - Annals of the Rheumatic Diseases, 2023

Cited by 0 Semantic Scholar

POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE OA

R. Westhovens, R. Alten, L. Dagna, A. Kavanaugh, K. Winthrop - Annals of the Rheumatic Diseases, 2023

Cited by 2 Semantic Scholar

AB1094 GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OA

A. Kavanaugh, E. Soriano, J. Dutz, C. Selmi, J. Yu - Annals of the Rheumatic Diseases, 2023

Cited by 0 Semantic Scholar

AB1096 IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NON-RESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES OA

D. McGonagle, D. Haaland, P. Helliwell, M. Marrache, M. Shawi - Annals of the Rheumatic Diseases, 2023

Cited by 0 Semantic Scholar

P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis OA

D. McGonagle, A. Kavanaugh, I. McInnes, L. Kristensen, J. Merola - Rheumatology, 2023

Cited by 0 Semantic Scholar

AB1118 EFFECT OF APREMILAST ON PSORIATIC DISEASE DOMAINS STRATIFIED BY EXTENT OF SKIN INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS OA

A. Wells, L. Teng, S. Colgan, C. Deignan, S. Jardon - Annals of the Rheumatic Diseases, 2023

Cited by 0 Semantic Scholar

AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES OA

P. Taylor, A. Kavanaugh, P. Nash, J. Pope, G. Pongratz - Annals of the Rheumatic Diseases, 2023

Cited by 1 Semantic Scholar

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial OA

P. Helliwell, P. Mease, A. Kavanaugh, L. Coates, A. Ogdie - RMD Open, 2022

Cited by 4 Semantic Scholar

AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis OA

C. Ritchlin, L. Kristensen, B. Strober, A. Kavanaugh, R. Bolce - Annals of the Rheumatic Diseases, 2022

Cited by 0 Semantic Scholar

Research Topics

Rheumatoid Arthritis Research and Therapies (19) Systemic Lupus Erythematosus Research (13) Monoclonal and Polyclonal Antibodies Research (11) Cell Adhesion Molecules Research (10) Autoimmune and Inflammatory Disorders Research (8)

Frequent Co-Authors

Laurie S. Davis

4 joint publications

Larry W. Moreland

3 joint publications

Peter E. Lipsky

3 joint publications

Daniel E. Fürst

2 joint publications

Dinesh Khanna

2 joint publications

Stanley Cohen

2 joint publications

Affiliations

Università Cattolica del Sacro Cuore

IT 2012 - 2012

Cedars-Sinai Medical Center

US 2009 - 2009

Nottingham University Hospitals NHS Trust

GB 2010 - 2010

University of San Diego

US 2012 - 2012

Simmons University

US 1995 - 1995

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers

Arthur F. Kavanaugh

Publication & Citation Trends

Most Cited Works

Publications

AB1107 PSORIATIC ARTHRITIS: IMPROVEMENT IN OUTCOMES BUT PERSISTENT SEX DIFFERENCE - 5 YEAR FOLLOW UP STUDY OF A NORWEGIAN OUTPATIENT CLINIC POPULATION OA

POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS OA

POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE OA

AB1094 GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OA

AB1096 IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NON-RESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES OA

P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis OA

AB1118 EFFECT OF APREMILAST ON PSORIATIC DISEASE DOMAINS STRATIFIED BY EXTENT OF SKIN INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS OA

AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES OA

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial OA

AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis OA

Research Topics

Frequent Co-Authors

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back